Proprotein Convertase 9

"Proprotein Convertase 9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A proprotein convertase that is essential for CHOLESTEROL homeostasis. It binds to and is required for the lysosomal degradation of the LDL RECEPTOR (LDLR); the VLDL receptor, and the APOLIPOPROTEIN E RECEPTOR. It also regulates neuronal APOPTOSIS.

Descriptor ID	D000071449
MeSH Number(s)	D08.811.277.656.300.760.718 D08.811.277.656.837.688 D08.811.277.656.959.350.718
Concept/Terms	Proprotein Convertase 9 Proprotein Convertase 9 Convertase 9, Proprotein Neural Apoptosis-Regulated Convertase 1 Neural Apoptosis Regulated Convertase 1 NARC-1 Protein NARC 1 Protein Proprotein Convertase, Subtilisin-Kexin Type 9 Proprotein Convertase, Subtilisin Kexin Type 9

Below are MeSH descriptors whose meaning is more general than "Proprotein Convertase 9".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Hydrolases [D08.811.277]
Peptide Hydrolases [D08.811.277.656]
Endopeptidases [D08.811.277.656.300]
Serine Endopeptidases [D08.811.277.656.300.760]
Proprotein Convertase 9 [D08.811.277.656.300.760.718]
Proprotein Convertases [D08.811.277.656.837]
Proprotein Convertase 9 [D08.811.277.656.837.688]
Serine Proteases [D08.811.277.656.959]
Serine Endopeptidases [D08.811.277.656.959.350]
Proprotein Convertase 9 [D08.811.277.656.959.350.718]

Below are MeSH descriptors whose meaning is related to "Proprotein Convertase 9".

Below are MeSH descriptors whose meaning is more specific than "Proprotein Convertase 9".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Proprotein Convertase 9" by people in this website by year, and whether "Proprotein Convertase 9" was a major or minor topic of these publications.

Bar chart showing 9 publications over 5 distinct years, with a maximum of 3 publications in 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2017	0	2	2
2018	2	1	3
2019	0	1	1
2020	1	0	1
2022	1	1	2

Below are the most recent publications written about "Proprotein Convertase 9" by people in Profiles.

Punch E, Klein J, Diaba-Nuhoho P, Morawietz H, Garelnabi M. Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis. J Am Heart Assoc. 2022 02; 11(3):e023328.

View in: PubMed
Zheng C, Liang SQ, Liu B, Liu P, Kwan SY, Wolfe SA, Xue W. A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver. Mol Ther. 2022 03 02; 30(3):1343-1351.

View in: PubMed
Watts JK, Ockene IS. RNA Interference for the Masses? siRNA Targeting PCSK9 Promises Prevention of Cardiovascular Disease. Nucleic Acid Ther. 2020 02; 30(1):1-3.

View in: PubMed
Cannon CP, Sanchez RJ, Klimchak AC, Khan I, Sasiela WJ, Reynolds MR, Rosenson RS. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease. Am J Cardiol. 2019 04 15; 123(8):1202-1207.

View in: PubMed
Edraki A, Mir A, Ibraheim R, Gainetdinov I, Yoon Y, Song CQ, Cao Y, Gallant J, Xue W, Rivera-P?rez JA, Sontheimer EJ. A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In?Vivo Genome Editing. Mol Cell. 2019 Feb 21; 73(4):714-726.e4.

View in: PubMed
Ibraheim R, Song CQ, Mir A, Amrani N, Xue W, Sontheimer EJ. All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo. Genome Biol. 2018 09 19; 19(1):137.

View in: PubMed
Ochin CC, Garelnabi M. Berberine Encapsulated PLGA-PEG Nanoparticles Modulate PCSK-9 in HepG2 Cells. Cardiovasc Hematol Disord Drug Targets. 2018; 18(1):61-70.

View in: PubMed
Yin H, Song CQ, Suresh S, Wu Q, Walsh S, Rhym LH, Mintzer E, Bolukbasi MF, Zhu LJ, Kauffman K, Mou H, Oberholzer A, Ding J, Kwan SY, Bogorad RL, Zatsepin T, Koteliansky V, Wolfe SA, Xue W, Langer R, Anderson DG. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat Biotechnol. 2017 Dec; 35(12):1179-1187.

View in: PubMed
Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017 09 01; 2(9):959-966.

View in: PubMed

People

Explore

Similar Concepts

Top Journals